Health state
|
HPV genotype
|
Canadian data
|
References
|
Base case estimates †
|
North America data
|
Sensitivity analysis estimates‡
|
References
|
---|
|
16/18
|
24.9%
|
[45]
|
24.9%
|
25.6%
|
22.0%
|
[60]
|
CIN1
|
CP*
|
33.6%
| |
33.6%
|
67.5%
|
57.0%
| |
|
6/11
|
4.8%
| |
4.8%
|
7.6%
|
6.0%
| |
|
Other
|
6.9%
| |
36.7%
|
17.8%
|
15.0%
| |
|
16/18
|
56.2%
|
[45]
|
56.2%
|
55.2%
|
50.0%
|
[60]
|
CIN2/3
|
CP*
|
32.9%
| |
32.9%
|
49.6%
|
45.0%
| |
|
Other
|
2.5%
| |
10.9%
|
5.6%
|
5.0%
| |
|
16/18
|
74.3%
|
[45]
|
74.3%
|
76.5%
|
85.0%
|
[60]
|
Cancer
|
CP*
|
18.3%
| |
18.3%
|
13.6%
|
15.0%
| |
|
Other
|
2.2%
| |
7.4%
|
1.0%
|
0.0%
| |
Genital Warts
|
6/11
| |
[61]
|
76.2%
| |
76.2%
|
[61]
|
- * CP: Cross-protection – oncogenic HPV types affected by the vaccine: HPV-31,-33,-35,-39,-45,-51,-52,-56,-58,-59.
- † The proportion in the other HPV category was increased as required so that all cervical outcomes were associated with an HPV infection.
- ‡ The sum of proportions of all HPV infections were equal to more than 100% for CIN1 and CIN2/3 lesions due to multiple HPV infections. For modelling purposes, the values in each HPV category were proportionally reduced so that sum of all HPV types equals 100% .
- CC – Cervical cancer.
- CIN – Cervical Intraepithelial Neoplasia.
- HPV – Human papillomavirus.